Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells invitro

Experimental Hematology

Volumn 42, Issue 7, 2014, Pages 516-525

  Bolomsky, Arnold ^a   Schreder, Martin ^a   Meißner, Tobias ^b   Hose, Dirk ^b   Ludwig, Heinz ^a   Pfeifer, Sabine ^a   Zojer, Niklas ^a  

^a WILHELMINEN HOSPITAL   (Austria)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; ALKALINE PHOSPHATASE; BORTEZOMIB; DICKKOPF 1 PROTEIN; GREMLIN 1; IMMUNOMODULATING AGENT; INHIBIN A; LENALIDOMIDE; PLEIOTROPHIN; THALIDOMIDE; TRANSCRIPTION FACTOR DLX5; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ARTICLE; BONE DEVELOPMENT; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCHYMAL STROMA CELL; OSTEOBLAST; PRIORITY JOURNAL; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; CELL DIFFERENTIATION; CELLS, CULTURED; HUMANS; MESENCHYMAL STROMAL CELLS; OSTEOBLASTS; THALIDOMIDE;

EID: 84904859122     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2014.03.005     Document Type: Article

References (57)

1. Roodman G.D. Pathogenesis of myeloma bone disease. Leukemia 2009, 23:435-441.
2. Raje N., Roodman G.D. Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res 2011, 17:1278-1286.
3. Tian E., Zhan F., Walker R., et al. The role of the wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349:2483-2494.
4. Giuliani N., Colla S., Morandi F., et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005, 106:2472-2483.
5. Oshima T., Abe M., Asana J., et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005, 106:3160-3165.
6. Colucci S., Brunetti G., Oranger A., et al. Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J 2011, 1:e27.
7. Terpos E., Christoulas D., Katodritou E., et al. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer 2012, 131:1466-1471.
8. Vallet S., Mukherjee S., Vaghela N., et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A 2010, 107:5124-5129.
9. Standal T., Abilgaard N., Fagerli U.M., et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007, 109:3024-3030.
10. Takeuchi K., Abe M., Hiasa M., et al. TGF-β inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS ONE 2010, 5:e9870.
11. He J., Liu Z., Zheng Y., et al. p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction. Cancer Res 2012, 72:6393-6402.
12. Rahmouni A., Divine M., Mathieu D., et al. MR appearance of multiple myeloma of the spine before and after treatment. AJR Am J Roentgenol 1993, 160:1053-1057.
13. Pozzi S., Raje N. The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. Oncologist 2011, 16:651-662.
14. Giuliani N., Morandi F., Tagliaferri S., et al. The proteasome inhibitor bortezomib affects osteoblast differentiation invitro and invivo in multiple myeloma patients. Blood 2007, 110:334-338.
15. De Matteo M., Brunetti A.E., Maiorano E., Cafforio P. Constitutive down-regulation of Osterix in osteoblasts from myeloma patients. Invitro effect of Bortezomib and Lenalidomide. Leuk Res 2010, 34:243-249.
16. Pennisi A., Li X., Ling W., Khan S., Zangari M., Yaccoby S. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bone invivo. Am J Hematol 2009, 84:6-14.
17. Zangari M., Esseltine D., Lee C.K., et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005, 131:71-73.
18. Ghandi A.K., Kang J., Capone L., et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010, 10:155-167.
19. Pal R., Monaghan S.A., Hassett A.C., et al. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia. Blood 2010, 115:605-614.
20. Breitkreutz I., Raab M.S., Vallet S., et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008, 22:1925-1932.
21. Munemasa S., Sakai A., Kuroda Y., et al. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol 2008, 33:129-136.
22. Scullen T., Santo L., Vallet S., et al. Lenalidomide in combination with an activin-A neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy. Leukemia 2013, 27:1715-1721.
23. Hose D., Moreaux J., Meissner T., et al. Induction of angiogenesis by normal and malignant plasma cells. Blood 2009, 114:128-143.
24. Wu Z., Irizarry R.A. Preprocessing of oligonucleotide array data. Nat Biotechnol 2004, 22:656-658.
25. Johnson W.E., Rabinovic A., Li C. Adjusting batch effects in microarray expression data using Empirical Bayes methods. Biostatistics 2007, 8:118-127.
26. Smyth G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3. Article3.
27. Benjamini Y., Hochberg Y. Controlling the false discovery: a practical and powerful approach to multiple testig. J R Stat Soc Series B 1995, 57:289-300.
28. Gentleman R.C., Carey C.J., Bates D.M., et al. Bioconductor open software development for computational biology and bioinformatics. Genome Biol 2004, 5:R80.
29. Chen N., Lau H., Kong L., et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007, 47:1466-1475.
30. Patil C.R., Bhise S.B. Re-emergence of thalidomide. Indian Journal of Pharmacology 2003, 35:204-212.
31. Lund T., Kent S., Abildgaard N., et al. First line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation invitro. Eur J Haematol 2010, 85:290-299.
32. Zangari M., Yaccobi S., Cavallo F., Esseltine D., Tricot G. Response to bortezomib and activtivation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma 2006, 7:109-114.
33. Tosi P., Zamagni E., Cellini C., et al. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Eur J Haematol 2006, 76:399-404.
34. Terpos E., Christoulas D., Kastritis E., et al. The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group. Am J Hematol 2014, 89(1):34-40.
35. Terpos E., Kastritis E., Christoulas D., et al. Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Ann Oncol 2012, 23:2681-2686.
36. Terpos E., Kastritis E., Roussou M., et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008, 22:2247-2256.
37. Colla S., Zhan F., Xiong W., et al. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood 2007, 109:4470-4477.
38. Yun-Feng W., Matsuo N., Sumiyoshi H., Yoshioka H. Sp7/Osterix up-regulates the mouse pro-alpha3(V) collagen gene (Col5a3) during the osteoblastic differentiation. Biochem Biophys Res Commun 2010, 394:503-508.
39. Muruganandan S., Roman A.A., Sinal C.J. Role of chemerin/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bone marrow stromal cells. J Bone Miner Res 2010, 25:222-234.
40. Cheng H., Qiu L., Ma J., et al. Replicative senescence of human bone marrow and umbilical cord derived mesenchymal stem cells and their differentiation to adipocytes and osteoblasts. Mol Biol Rep 2011, 38:5161-5168.
41. Gale Z., Cooper P.R., Scheven B.A. Glial cell line-derived neurotrophic factor influences proliferation of osteoblastic cells. Cytokine 2012, 57:276-281.
42. Choi H.D., Noh W.C., Park J.W., Lee J.M., Suh J.Y. Analysis of gene expression during mineralization of cultured human periodontal ligament cells. J Periodontal Implant Sci 2011, 41:30-43.
43. Baniwal S.K., Shah P.K., Shi Y., et al. Runx2 promotes both osteoblastogenesis and novel osteoclastogenic signals in ST2 mesenchymal progenitor cells. Osteoporos Int 2012, 23:1399-1413.
44. Pollari S., Käkönen S.M., Edgren H., et al. Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis. Breast Cancer Res Treat 2011, 125:421-430.
45. Schulze J., Bickert T., Beil F.T., et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J Bone Miner Res 2011, 26:704-717.
46. Long F. Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol 2011, 13:27-38.
47. Chen H., Gordon M.S., Campbell R.A., et al. Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth. Blood 2007, 110:287-295.
48. Chen H., Campbell R.A., Chang Y., et al. Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular cells: a novel mechanism of tumor-induced vasculogenesis. Blood 2009, 113:1992-2002.
49. Travella S., Ruggiu A., Giuliani A., et al. Bone turnover in wild type and pleiotrophin-transgenic mice housed for three months in the International Space Station (ISS). PLoS One 2012, 7:e33179.
50. Trost Z., Trebse R., Prezelj J., Komadina R., Logar D.B., Marc J. A microarray based identification of osteoporosis-related genes in primary culture of human osteoblasts. Bone 2010, 46:72-80.
51. Tang K.T., Capparelli C., Stein J.L., et al. Acidic fibroblast growth factor inhibits osteoblast differentiation invitro: altered expression of collagenase, cell growth-related, and mineralization-associated genes. JCell Biochem 1996, 61:152-166.
52. Gazzero E., Pereira R.C., Jorgetti V., Olson S., Economides A.N., Canalis E. Skeletal overexpression of gremlin impairs bone formation and causes osteopenia. Endocrinology 2005, 146:655-665.
53. Zhu F., Friedman M.S., Luo W., Woolf P., Hankenson K.D. The transcription factor osterix (SP7) regulates BMP6-induced human osteoblast differentiation. J Cell Physiol 2012, 227:2677-2685.
54. Rehn A.P., Cerny R., Sugars R.V., Kaukua N., Wendel M. Osteoadherin is upregulated by mature osteoblasts and enhances their invitro differentiation and mineralization. Calcif Tissue Int 2008, 82:454-464.
55. Kalamajski S., Aspberg A., Lindblom K., Heinegard D., Oldberg A. Asporin competes with decorin for collagen binding, binds calcium and promotes osteoblast collagen mineralization. Biochem J 2009, 423:53-59.
56. Ito T., Ando H., Suzuki T., et al. Identification of a primary target of thalidomide teratogenicity. Science 2010, 327:1345-1350.
57. Lu G., Middleton R.E., Sun H., et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins. Science 2014, 343:305-309.